-
1.发明申请METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH 有权从具有非扩散性突变的DNA生产功能性蛋白质的方法和与之相关的疾病的治疗方法公开(公告)号：US20110046136A1
公开(公告)日：2011-02-24
申请号：US12294952
申请日：2007-03-29
申请人： Neil G. Almstead , Guangming Chen , Hirawat Samit , Peter Seongwoo Hwang , Gary M. Karp , Langdon Miller , Young-Choon Moon , Hongyu Ren , James J. Takasugi , Ellen M. Welch , Richard G. Wilde , Paul Kennedy
发明人： Neil G. Almstead , Guangming Chen , Hirawat Samit , Peter Seongwoo Hwang , Gary M. Karp , Langdon Miller , Young-Choon Moon , Hongyu Ren , James J. Takasugi , Ellen M. Welch , Richard G. Wilde , Paul Kennedy
IPC分类号： A61K31/4245 , A61K31/5377 , A61K31/496 , A61K31/454 , A61K31/4709 , A61K31/4439 , A61K31/519 , A61K31/498 , A61K31/53 , A61K31/506 , A61K31/497 , A61K31/501 , A61K31/433 , A61K31/421 , A61K31/415 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/42 , A61K31/4164 , A61K31/34 , A61K31/381 , A61K31/4196 , A61P21/00 , A61P11/00 , A61P7/00 , A61P25/00 , A61P13/12 , A61P27/02
CPC分类号： A61K31/4245 , A61K31/00 , A61K31/40 , A61K31/41 , A61K31/4162 , A61K31/44 , A61K31/46
摘要： The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
摘要翻译： 本发明涉及由包含无义突变的核酸序列编码的功能性蛋白质。 本发明还涉及用于产生由包含无义突变的核酸序列编码的功能性蛋白质的方法以及用于预防，管理和/或治疗与基因中的无义突变有关的疾病的这些蛋白质的用途。
-
2.发明申请Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, composistions thereof and the use for nonsense suppression 有权羟基化的1,2,4-恶二唑苯甲酸化合物及其组合物，以及废物抑制的用途公开(公告)号：US20080139632A1
公开(公告)日：2008-06-12
申请号：US11904001
申请日：2007-09-24
IPC分类号： A61K31/4245 , C12N5/06 , C12N5/08 , A61P35/00 , C07D271/06
CPC分类号： A61K31/4245 , C07D271/06
摘要： Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
摘要翻译： 公开了新型羟基化的1,2,4-恶二唑苯甲酸化合物，使用方法和包含羟基化的1,2,4-恶二唑苯甲酸衍生物的药物组合物。 所述方法包括治疗或预防通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病或改善与其相关的一种或多种症状的方法。
-
3.发明授权Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and their use in bioassays 有权羟基化的1,2,4-恶二唑苯甲酸化合物，其组合物及其在生物测定中的用途公开(公告)号：US08691511B2
公开(公告)日：2014-04-08
申请号：US13327816
申请日：2011-12-16
IPC分类号： C12Q1/68 , C07D271/06 , A61K31/41 , C12P21/04
CPC分类号： A61K31/4245 , C07D271/06
摘要： Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
摘要翻译： 公开了新型羟基化的1,2,4-恶二唑苯甲酸化合物，使用方法和包含羟基化的1,2,4-恶二唑苯甲酸衍生物的药物组合物。 所述方法包括治疗或预防通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病或改善与其相关的一种或多种症状的方法。
-
4.发明申请HYDROXYLATED 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS THEREOF AND THEIR USE IN BIOASSAYS 有权羟基苯氧基-1,2,4-氧杂二苯甲酸化合物，其组合物及其在生物利用中的应用公开(公告)号：US20120087896A1
公开(公告)日：2012-04-12
申请号：US13327816
申请日：2011-12-16
IPC分类号： A61K35/76 , A61K35/12 , A61K35/74 , A61P3/10 , A61P35/00 , A61P11/00 , A61P25/28 , A61P25/16 , A61P9/10 , A61P25/00 , A61P3/04 , C12Q1/68 , A61P9/00
CPC分类号： A61K31/4245 , C07D271/06
摘要： Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
摘要翻译： 公开了新型羟基化的1,2,4-恶二唑苯甲酸化合物，使用方法和包含羟基化的1,2,4-恶二唑苯甲酸衍生物的药物组合物。 所述方法包括治疗或预防通过调节过早翻译终止或无义介导的mRNA衰变改善的疾病或改善与其相关的一种或多种症状的方法。
-
5.发明授权Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof 有权羟基化的1,2,4-恶二唑苯甲酸化合物及其组合物公开(公告)号：US08101641B2
公开(公告)日：2012-01-24
申请号：US11904001
申请日：2007-09-24
IPC分类号： A61K31/4245 , C07D271/06
CPC分类号： A61K31/4245 , C07D271/06
摘要： Novel hydroxylated 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising a hydroxylated 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.
摘要翻译： 公开了新型羟基化的1,2,4-恶二唑苯甲酸化合物，使用方法和包含羟基化的1,2,4-恶二唑苯甲酸衍生物的药物组合物。 所述方法包括治疗或预防通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病或改善与其相关的一种或多种症状的方法。
-
公开(公告)号：US20100063297A1
公开(公告)日：2010-03-11
申请号：US12617757
申请日：2009-11-13
IPC分类号： C07D271/06
CPC分类号： C07D271/06
摘要： Provided herein are processes for the preparation of compounds useful for the treatment, prevention or management of diseases associated with a nonsense mutation. More specifically, provided herein are processes for the synthesis of 1,2,4-oxadiazoles. In particular, provided herein are processes useful for the preparation of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid.
摘要翻译： 本文提供了制备用于治疗，预防或控制与无义突变有关的疾病的化合物的方法。 更具体地，本文提供了合成1,2,4-恶二唑的方法。 特别地，本文提供了可用于制备3- [5-（2-氟苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的方法。
-
![Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid](/abs-image/US/2008/07/17/US20080171377A1/abs.jpg.150x150.jpg)
7.发明申请Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid 有权结晶形式的3- [5-（2-氟苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸公开(公告)号：US20080171377A1
公开(公告)日：2008-07-17
申请号：US11904005
申请日：2007-09-24
IPC分类号： C12N1/00 , C07D271/06
CPC分类号： A61K31/4245 , C07D271/06
摘要： The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.
摘要翻译： 本发明涉及3- [5-（2-氟苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的结晶形式，包含结晶形式的药物组合物和剂型， 它们用于治疗，预防或控制通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病的结晶形式和方法。
-
公开(公告)号：US20080139818A1
公开(公告)日：2008-06-12
申请号：US11899813
申请日：2007-09-06
IPC分类号： C07D271/06
CPC分类号： C07D271/06
摘要： Provided herein are processes for the preparation of compounds useful for the treatment, prevention or management of diseases associated with a nonsense mutation. More specifically, provided herein are processes for the synthesis of 1,2,4-oxadiazoles. In particular, provided herein are processes useful for the preparation of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid.
摘要翻译： 本文提供了制备用于治疗，预防或控制与无义突变有关的疾病的化合物的方法。 更具体地，本文提供了合成1,2,4-恶二唑的方法。 特别地，本文提供了可用于制备3- [5-（2-氟苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的方法。
-
![CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID](/abs-image/US/2011/02/17/US20110040100A1/abs.jpg.150x150.jpg)
9.发明申请CRYSTALLINE FORMS OF 3-[5-(2-FLUOROPHENYL)-[1,2,4]OXADIAZOL-3-YL]-BENZOIC ACID 有权3- [5-（2-氟 - 戊基） - [1,2,4]氧杂双环[3-y]] - 苯甲酸的晶体形式公开(公告)号：US20110040100A1
公开(公告)日：2011-02-17
申请号：US12913213
申请日：2010-10-27
IPC分类号： C07D271/06
CPC分类号： A61K31/4245 , C07D271/06
摘要： The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.
摘要翻译： 本发明涉及3- [5-（2-氟苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的结晶形式，包含结晶形式的药物组合物和剂型， 它们用于治疗，预防或控制通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病的结晶形式和方法。
-
![Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid](/abs-image/US/2011/01/04/US07863456B2/abs.jpg.150x150.jpg)
10.发明授权Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid 有权结晶形式的3- [5-（2-氟苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸公开(公告)号：US07863456B2
公开(公告)日：2011-01-04
申请号：US11904005
申请日：2007-09-24
IPC分类号： C07D271/06
CPC分类号： A61K31/4245 , C07D271/06
摘要： The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.
摘要翻译： 本发明涉及3- [5-（2-氟苯基） - [1,2,4]恶二唑-3-基] - 苯甲酸的结晶形式，包含结晶形式的药物组合物和剂型， 它们用于治疗，预防或控制通过调节过早翻译终止或无义介导的mRNA衰变而改善的疾病的结晶形式和方法。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.036 秒)
